Specify Company / Ticker to Get the Summary
Dividend History SYBX
Dividend Analytics SYBX
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Synlogic Inc
SYBXSynlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Address: PO Box 30, Winchester, MA, United States, 01890
Analytics
WallStreet Target Price
1.00 USDP/E Ratio
5.36Dividend Yield
–Financials SYBX
Results | 2019 | Dynamics |